Amantadine for Parkinson's disease
Amantadine for Parkinson's disease
复制标题
金刚烷胺治疗帕金森病
DOI：
10.1212/wnl.21.9.958
复制
发表时间：
1971
期刊：
影响因子：
9.9
通讯作者：
L. Waterbury
中科院分区：
文献类型：
--
作者：
Donald C. Mann;L. A. Pearce;L. Waterbury
Schwab等人在1969年进行的一项非对照试验中首次报告盐酸金刚烷胺可有效治疗帕金森病。在随后的对照研究中，Parkes等人2报告称，在接受治疗的35例患者中，大多数显示出临床改善。在这些患者中使用更高剂量时，额外的反应是~ B t。~另一方面，Hunter等4发现金刚烷胺对功能残疾无显著影响。在上述所有研究中，金刚烷胺与患者既往抗帕金森病药物联合给药。在本研究中，在双盲交叉研究中确定了盐酸金刚烷胺（Symmetrela）单独使用的有效性，并确定了其对常规实验室检查、脑电图（EEG）和胺代谢的影响。
AMANTADINE HYDROCHLORIDE was first reported to be effective in the treatment of Parkinson’s disease by Schwab et a1.l in an uncontrolled trial done in 1969. In subsequent controlled studies, Parkes et al.2 reported that of 35 patients treated, most showed clinical improvement. Using higher doses in these patients, an additional response was ~ b t a i n e d . ~ On the other hand, Hunter et al.4 found that amantadine had no significant effect on functional disability. In all of the above studies, amantadine was given in combination with the patient’s previous antiparkinsonian medications. In the present investigation, the effectiveness of amantadine hydrochloride ( Symmetrela) alone was established in a doubleblind crossover study, and its effects, upon routine laboratory tests, electroencephalography (EEG), and amine metabolism were determined.